FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Sunday

 

Decreased expression of IL-33 in immune thrombocytopenia: STUDY




























Image Source:THINKINGMACHINEBLOG


Abstract

Purpose:
Interleukin-33 (IL-33) is an IL-1 family cytokine which signals via its ST2 receptor and is involved in several autoimmune diseases by regulating T cell immune responses. This study aims to measure the expression of soluble ST2 (sST2) and IL-33 in active immune thrombocytopenia (ITP) and during remission.

Methods:
Thirty-two ITP patients with active disease and 20 patients in remission were studied. IL-33 and sST2 were measured in plasma using ELISA and compared with 27 age- and sex-matched healthy controls. Real-time quantitative PCR was used to determine IL-33 and sST2 mRNA expressions.

Results:
The IL-33 level in plasma was significantly down-regulated in the patients with active ITP (P < 0.01). The sST2 level was up-regulated (P < 0.01) in the patients with active ITP compared with ITP in remission and the normal controls. No significant changes were detected between the patients with ITP in remission and the normal controls. We detected an obvious up-regulation of sST2 mRNA levels but no change in IL-33 mRNA expression. There was no correlation observed between IL-33 or sST2 expression and the platelet count of the patients with active ITP. The plasma and mRNA level ratios of sST2/IL-33 were up-regulated in the active disease patients (P < 0.01). However, no difference was detected between the ITP patients with remission disease and healthy controls.

Conclusions:
The values of sST2 and IL-33 observed in patients with ITP correlated with disease activity. Considering the role of IL-33 in regulating T cell immunity, studies on IL-33 and sST2 in ITP would further improve our understanding of the pathogenesis of ITP.

Story Source: The above story is based on materials provided by SCIENCEDIRECT
Note: Materials may be edited for content and length

Labels:



Go to Newer News Go to Older News